This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BD Rx Announces FDA Approval Of High-Demand Injectable For Pain Management

FRANKLIN LAKES, N.J., Nov. 4, 2013 /PRNewswire/ --  BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that the U.S. Food and Drug Administration (FDA) has approved Morphine Sulfate Injection, USP to be offered in the BD Simplist line of ready-to-administer prefilled injectables in the most common strengths:  2mg/mL, 4mg/mL, 5mg/mL, 8mg/mL and 10mg/mL. Morphine Sulfate Injection, USP is indicated for the management of pain not responsive to non-narcotic analgesics.

"The launch of an FDA approved morphine product at a time of heightened need is an important step in our plans to drive clinical practice improvements," said Mark Sebree, President, BD Rx. "The expansion of the BD Simplist product line demonstrates our commitment to providing our hospital and surgical center customers with drugs in high-demand today."

BD Rx will begin production of morphine immediately and projects initial product availability in early calendar year 2014.

This approval marks the fourth in a series of 20 to 30 drugs that BD Rx plans to launch in the BD Simplist prefilled injectables product line in the coming years. The first three drugs launched in the past year are Diphenhydramine Hydrochloride Injection, USP, Metoclopramide Injection, USP and Ondansetron Injection, USP 4mg/2mL (2mg/2mL). The company plans to focus on the therapeutic categories primarily used by clinicians in the hospital and surgical center settings, including pain management, anesthetics, cardiovascular agents and antiemetics.

BD Simplist prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, helping to reduce the potential risk of medication error and allowing for more focus on the patient and less on injection preparation. Clinicians perform up to 20 steps in a traditional vial and syringe injection sequence. BD Simplist prefilled injectables reduce the injection sequence to approximately 12 steps.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.85 -58.33 -2.96%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs